openPR Logo
Press release

Cancer Immunotoxins Market Cancer Immunotoxins Clinical Pipeline Report 2020

07-11-2017 12:25 PM CET | Health & Medicine

Press release from: Kuick Resarch

Cancer Immunotoxins Market Cancer Immunotoxins Clinical

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

1. Introduction to Immunotoxins

2. Immunotoxins: The Three Generations & Advancements

3. Sources of Toxins
3.1 Plant Toxins
3.2 Bacterial Toxins

4. Production of Immunotoxins

5. Types of Immunotoxins
5.1 Anthrax Based Toxins
5.2 Diphtheria Toxin (DT) & DT Derivatives
5.3 Pseudomonas Exotoxin (PE) & PE Derivatives
5.4 Ribosome Inactivating Proteins Based Immunotoxins
5.4.1 Ricin
5.4.2 Saporin based Immunotoxins
5.4.3 Recombinant Constructs of RIP I Toxins
5.5 Ribonucleases based Immunotoxins
5.6 Proapoptotic Proteins as Targeted Immunotoxins

6. Cancer Immunotoxins Therapy Analysis
6.1 Immunotoxins for Hematologic Malignancies
6.1.1 Denileukin Diftitox (ONTAK, DAB389IL-2)
6.1.2 LMB-2 (anti-Tac[Fv]-PE38)
6.1.3 Moxetumomab Pasudotox
6.1.4 A-dmDT390-bisFv (UCHT1)
6.1.5 DT2219ARL
6.1.6 HuM195-Gelonin
6.2 Immunotoxins for Solid Tumors
6.2.1 SS1P
6.2.2 RG7787
6.2.3 Oportuzumab Monatox
6.2.4 VB6-845
6.2.5 D2C7-(scdsFv)-PE38KDEL

7. Advantages of Immunotoxins upon other Anticancerous Drugs

8. Applications of Immunotoxins
8.1 Immunotoxins against Solid Tumors
8.1.1 Immunotoxin against Colon Carcinoma
8.1.2 Immunotoxin against Breast Cancer & Sarcoma
8.1.3 Immunotoxin against Glioma & Head & Neck Squamous Cell Carcinoma
8.1.4 Immunotoxin against Prostate & Lung Cancer
8.2 Immunotoxins against Leukemias
8.3 Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs

9. Global Cancer Immunotoxins Market Outlook
9.1 Current Market Scenario
9.2 Cancer Immunotoxins Clinical Pipeline Overview

10. Global Cancer Immunotoxins Market Dynamics
10.1 Favorable Parameters
10.1.1 Large Segment of Patient Still Devoid of Appropriate Medication
10.1.2 Cancer: A Severe Pathological Condition
10.1.3 Unmet Requirement of Completely Curative Agents
10.1.4 Unwanted Effects of the Existing Drugs
10.2 Commercialization Challenges
10.2.1 Stern Regulatory Guidelines: A Major Hurdle
10.2.2 Never Ending Phase of Research & Development
10.2.3 Conduction of Clinical Trials
10.2.4 Funding Research & Development: A Super Costly Affair
10.2.5 Immunogenicity of Immunotoxins

11. Global Cancer Immunotoxins Market Future Prospects

12. Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-II/III
12.7 Phase-III

13. Discontinued & No Development in Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

14. Competitive Landscape
14.1 AbbVie
14.2 AbGenomics
14.3 Agensys
14.4 Ambrx
14.5 Amgen
14.6 AREVA Med
14.7 Bayer HealthCare
14.8 Biotest
14.9 Celldex Therapeutics
14.10 CuraGen Corporation
14.11 Genentech
14.12 Genmab
14.13 Heidelberg Pharma
14.14 ImmunoGen
14.15 Neurocrine Biosciences
14.16 Research Corporation Technologies
14.17 Sanofi
14.18 Seattle Genetics
14.19 Sorrento Therapeutics
14.20 Spirogen

Download Report: https://www.kuickresearch.com/report-Global-Cancer-Immunotoxins-Market-&-Clinical-Pipeline-Insight-2020.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cancer Immunotoxins Market Cancer Immunotoxins Clinical Pipeline Report 2020 here

News-ID: 618866 • Views: 103

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Immunotoxin

Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Report
“Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020” Report Highlights: * Introduction to Immunotoxins * Cancer Immunotoxins Therapy Analysis * Advantages of Immunotoxins upon other Anticancerous Drugs * Applications of Immunotoxins to Multiple Cancer Therapies * Global Cancer Immunotoxins Market Future Prospects * Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase * Global Cancer Immunotoxins Clinical Pipeline: 52 Cancer Immunotoxins * Majority Cancer Immunotoxins in Preclinical Phase: 21 Drugs Download Report Sample Weblink: https://www.kuickresearch.com/report-Global-Cancer-Immunotoxins-Market-&-Clinical-Pipeline-Insight-2020.php For Report Sample
Global Immunotoxins Market Set for Rapid Growth and Trend, by 2023
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Global Immunotoxins Market - Industry Size, Share, Growth, Trends and Forecast 2 …
"The Report Immunotoxins Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin.
Download Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Repo …
Immunotoxins are new generation chemotherapeutic agents innovated to include the specificity of monoclonal antibody and cytotoxicity of toxins extracted from plant or bacterial source. The targeting moiety carries the specificity of the antibody and is directed to the target where it either binds to the cell surface antigen, receptor or the ligand of the targeted disease. Cytotoxicity is mediated by the protein toxins, which maybe protein at times. The cytotoxic part
Immunotoxins Market Research Report | Growth Prospects, Key Opportunities, Trend …
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Global Cancer Immunotoxins Market Sales Revenue Clinical Trials Pipeline Report …
Immunotoxins are new generation chemotherapeutic agents innovated to include the specificity of monoclonal antibody and cytotoxicity of toxins extracted from plant or bacterial source. The targeting moiety carries the specificity of the antibody and is directed to the target where it either binds to the cell surface antigen, receptor or the ligand of the targeted disease. Cytotoxicity is mediated by the protein toxins, which maybe protein at times. Download Report: https://www.kuickresearch.com/report-Global-Cancer-Immunotoxins-Market-&-Clinical-Pipeline-Insight-2020.php For Report